HIMS Has Been a Roller Coaster Ride. Should Investors Hop On?

Hims & Hers reported its first profitable year in 2024 with net income of $126 million, a nearly 244% increase in net cash from operations year-over-year, and Q3 revenue of $598.98 million (+49.2% Y/Y) driven by a 50% rise in subscribers using personalized solutions. The company has delivered strong historical growth (average annual EBITDA +37.1%, revenue +77.9%, EPS +169.6% since 2021) and improved valuation metrics (forward P/E 52.8 vs. trailing 67.3), yet the stock has been highly volatile in 2025 despite being up ~139% since IPO. Strategically, HIMS sits at the convergence of multiple high-growth markets—telehealth, sexual-health and hair-care supplements, and the GLP-1 weight-loss market—and is in discussions with Novo Nordisk to potentially distribute Wegovy pending FDA approval. Analyst sentiment is cautious (consensus Reduce/Hold and a $45.27 12-month target implying ~24% upside), while very high short interest (37.5% of float) and strong institutional ownership (~64%, with ~$2.31bn inflows vs $1.17bn outflows last 12 months) present both material downside risk and signs of institutional conviction.

Analysis

Hims & Hers reported its first profitable year in 2024 with net income of $126 million and a near 244% increase in net cash from operating activities year-over-year, reflecting improved cash generation and tighter debt management. In Q3 the company posted revenue of $598.98 million, a 49.2% year-over-year increase, while missing earnings by $0.03; management attributes revenue growth to a 50% year-over-year rise in subscribers using personalized solutions.

Balance-sheet and valuation metrics show progress but still imply high growth expectations: debt-to-equity stands at 1.67, forward P/E is 52.79 versus a trailing 67.33, and consensus estimates imply EPS rising from $0.29 to $0.52 (roughly +79%). Historical growth since 2021 has been robust (average annual EBITDA +37.14%, revenue +77.85%, EPS +169.63%), supporting the premium multiple but leaving little margin for execution misses.

Strategically, HIMS sits at the intersection of high-CAGR markets—telehealth (24.68%), sexual-health (10.4%), hair thinning (10.85%) and GLP-1 weight loss (18.54%)—and is in talks with Novo Nordisk to distribute Wegovy pending FDA approval, which is a meaningful upside catalyst if realized. Offsetting opportunities, the stock has exhibited extreme 2025 volatility, short interest is elevated at 37.54% of float, analyst consensus leans Reduce/Hold despite a $45.27 12-month target (~24.5% upside), and institutional ownership (~64% with $2.31bn inflows vs $1.17bn outflows) signals mixed but significant conviction.

Key Decisions for Investors

• Consider a modest, size-constrained long exposure to HIMS to capture secular growth in telehealth and GLP-1 adjacency given 2024 profitability and strong cash-generation, but limit position size because the forward P/E (52.79) assumes continued rapid execution
• Monitor near-term catalysts closely—FDA outcome on Wegovy distribution talks with Novo Nordisk, quarterly subscriber trends and guidance—and treat positive developments as conviction boosters and misses as triggers to reduce exposure
• Protect capital against severe volatility and elevated short interest (37.54% of float) by using stop-losses, position hedges or options strategies rather than unhedged outright exposure